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Background
Contemporary sensitivity troponin (cs-cTn) concentrations 
above the upper limit of normal (ULN) are seen in a wide range 
of clinical conditions and evidence is growing that suggests cs-
cTn may be a biomarker of future morbidity and mortality.
Objectives
Our aim was to test the hypothesis that cs-cTn, measured in 
the emergency department, may be a biomarker for 30-day 
mortality, irrespective of the patient’s presentation.
Method
In all 5,708 consecutive cases, contemporary sensitivity 
troponin I (cs-cTnI) was measured either as requested by the 
clinical team or as part of the study, in which case both the 
clinical team and the patient were unaware of the result. Basic 
demographics were available from the original study and 30-
day mortality was derived from NHS Digital data.
Results
In patients whose cs-cTnI test was requested solely as part  
of the study, 30-day mortality increased with increasing  
cs-cTnI concentrations (0% with undetectable concentrations 
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to 14.7% with concentrations above the ULN). Multivariable 
Cox regression analysis showed that log(10)cs-cTnI 
concentration was independently associated with 30-day 
mortality.
Conclusion
Increasing cs-cTnI concentrations are associated with higher 
short-term mortality as well as length of stay. As such, cs-cTnI 
measurements may provide useful prognostic information.
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The recommended criteria for the diagnosis of a type 1 myocardial 
infarction (T1MI) require a rise in cardiac troponin (cTn) above 
the 99th percentile derived from a reference population of 
normal individuals, in association with relevant symptoms and 
ECG changes.1 Around 6% of patients arriving at the emergency 
department (ED) present with chest pain and the ability to manage 
these patients in a clinically effective and efficient manner is of 
paramount importance to healthcare systems.2 A key limitation with 
the initial cTn assays was that in order to achieve acceptable levels 
of sensitivity and specificity a sample was required 10–12 hours 
after the onset of chest pain. This stimulated the development of 
contemporary sensitivity cTn (cs-cTn) assays.3,4 These assays now 
demonstrate improved diagnostic performance within a few hours 
of admission, which has led to their widespread adoption in both 
clinical practice and guideline recommendations.1,3–6 Consequently, 
cs-cTn assays have reduced the number of patients admitted from 
ED with chest pain by approximately a third, with no cost in terms of 
adverse clinical outcomes.7,8
While the role of cs-cTn for rapid exclusion of myocardial 
infarction in patients presenting to ED has been well established, 
the potential clinical value of cs-cTn as a biomarker outside 
this context is unknown.9 There is, however, evidence that both 
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detected in patients presenting to ED, despite only a small 
proportion having a T1MI.10–16 In the CHARIOT study, we 
measured cs-cTn on 20,000 consecutive patients attending our 
institution for any reason, either inpatient or outpatient, with the 
aim of describing the true distribution and 99th percentile for 
cs-cTn in a hospital population.16 In the current study, we report 
the distribution of cs-cTn in the subpopulation of CHARIOT who 
attended ED and in whom the assay was taken regardless of 
whether there was a clinical indication, and we assess a possible 
association between the cs-cTn concentration and both 30-day 
mortality and length of stay. Our aim was to test the hypothesis 
that cs-cTn may be a biomarker for clinical outcome, irrespective of 
the indication for its measurement.
Materials and methods
Study population
This study included 5,708 consecutive patients over the 
age of 18, presenting to ED or eye casualty (EC), who had a 
biochemistry sample performed for any reason as part of their 
routine clinical care as directed by the supervising clinician at our 
institution in the UK. These patients are a subset of the CHARIOT 
study that were identified as being seen initially in either ED or 
EC via the unique sample location originator details included on 
the blood sample.16 The sample location details are required in 
order to process biochemistry samples at our institution. This 
study included all locators from ED and EC: EC, clinical decision 
unit (CDU), minor treatment area, major treatment area, 
resuscitation area and a generic ED code. Patients are triaged 
to these areas on arrival based on the perceived severity of their 
condition.
The methods of the CHARIOT study16 have been previously 
described but the key elements of this study are that CHARIOT 
was a prospective observational study of 20,000 patients over 
the age of 18 years undergoing biochemistry blood tests for 
any reason as part of their routine care in both the inpatient 
and outpatient settings. A contemporary sensitivity troponin I 
(cs-cTnI) test was added on to the first sample received for each 
patient during the study period. The patients were unaware 
that this test was being performed, and, unless requested by 
the clinician, the cs-cTnI result was not revealed to patient or 
their doctor. This study was performed in accordance with the 
principles of Good Clinical Practice and the Declaration of Helsinki 
and the study received relevant ethical and Health Research 
Authority UK approval (IRAS 215262, REC 17/SC/0042, CAG 
17/CAG/0022). In order to access the 30-day mortality for all 
patients, a major amendment was submitted and subsequently 
approved by both the Research Ethics Committee and the 
Confidentiality Advisory Group (IRAS 215262, REC 17/SC/0042, 
CAG 17/CAG/0083).
Troponin assay
The Beckman Coulter Access AccuTnI+3 assay (Beckman Coulter, 
Brea, USA) was used to measure cs-cTnI concentrations in 
CHARIOT because this was the higher-sensitivity cTn assay used in 
our trust for routine clinical care at the time of the study. The 99th 
percentile recommended by the manufacturer is 40 ng/L and this 
was therefore used as the upper limit of normal (ULN) in routine 
clinical practice in our institution.
Clinical outcome data
Basic demographic details, estimated glomerular filtration rate 
(eGFR), indication for the biochemistry sample and whether the 
cs-cTnI was requested by the clinical team were available from 
the original CHARIOT study. As prospectively planned, data from 
clinical coding were used to ascertain whether the patient was 
admitted, the length of stay and the discharge diagnosis. Where 
there was insufficient coding data, the individual electronic patient 
record was interrogated to provide these data. Further, NHS 
Digital were sent each patient’s NHS number, gender, date of birth 
and study-specific ID to allow them to match each patient with 
national mortality data to provide 30-day mortality.
Statistical analysis
Statistics were performed using SPSS V26.0 (IBM Corporation, 
Armonk, USA). Summary variables are reported as medians with 
interquartile ranges, with the number (and percentage) above 
the ULN and the actual 99th percentiles as appropriate. The 
Chi-squared test was used for comparison between categorical 
variables. The Mann–Whitney U test was used for comparison of 
continuous variables without a normal distribution. The primary 
outcome was 30-day mortality. The discriminatory ability of 
cs-cTnI for survival was tested by calculating receiver operator 
curves (ROC) and analysing the area under the curve (AUC). 
The sensitivity, specificity, positive predictive values (PPV) and 
negative predictive values (NPV) of specific concentrations of 
cs-cTnI were derived from the ROC analysis. Multivariable analysis 
was performed using a Cox proportional hazards model, with 
outputs presented as hazard ratios (HR) with 95% confidence 
intervals (CI). Cs-cTnI was log(10) transformed due to the highly 
positively skewed distribution of this variable. Covariables in this 
multivariable analysis were gender, age, sample location, whether 
the cs-cTnI was requested and the eGFR.17 Separate mortality 
analyses were completed for the whole population and for the 
patients in whom the admitting clinician did not suspect acute 
coronary syndrome and as such did not request a cs-cTnI test.
Patient and public involvement
The protocol of the original CHARIOT study was reviewed by the 
British Cardiac Patients Association and the group were supportive 
of the study design. In particular the group accepted that the lack 
of patient consent in the study was appropriate.
Results
Demographics of the whole cohort
The median age of the whole cohort was 56 years (interquartile 
range (IQR) 35–76 years). There were 63 (1.1%) samples from 
EC, with the remainder from ED: resuscitation 554 (9.7%), majors 
2,551 (44.7%), minors 451 (7.9%) and CDU 23 (0.4%), with the 
rest from a ‘generic ED’ location code 2066 (36.2%). The median 
cs-cTnI for the whole population was 7 ng/L (IQR 3–13), with 681 
(11.9%) having an undetectable cs-cTnI concentration and 491 
(8.6%) having a cs-cTnI above the ULN. The 99th percentile for 
the whole cohort was 755 ng/L. The frequency of cs-cTnI above 
the ULN increased with age: 25 (1.4%) aged 18–39 years, 45 
(3.3%) aged 40–59 years, 149 (10.4%) aged 60–79 years, 272 
(23.2%) aged 80 years and over.
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Clinician-requested samples and study only samples
The clinical team requested hs-cTnI in 1,551 (27.2%) of patients: 
none (0%) in EC, three (13.0%) in CDU, eight (1.8%) in minors, 688 
(27.0%) in majors, 123 (22.2%) in resuscitation and 729 (35.3%) 
generic ED. The median cs-cTnI for patients who had their cs-cTnI 
test requested by the supervising clinician was 7 ng/L (IQR 3–13). 
There were 512 (12.3%) with undetectable cs-cTnI concentrations 
and 309 (7.4%) with concentrations above the ULN. The 99th 
percentile for this cohort was 378 ng/L. Table 1 demonstrates the 
percentage of patients with cs-cTnI concentrations above the ULN 
based on their location and whether the test was requested by the 
clinical team. Fig 1 demonstrates the range of indications given for 
requesting cs-cTnI testing and the frequency with which the result 
was above the ULN.
There was no difference observed in age distribution between 
patients in whom the test was clinically requested and those in 
whom it was only performed as part of the study (56 years (IQR 
34–77) vs 56 years (IQR 34–77)). There were fewer males in the 
clinically requested cohort (42.9% vs 52.8%).
Outcome of ED visit
Five patients died in ED with a median age of 57: three of these 
had a cs-cTnI above the reference range (none of which were 
requested by the clinical team). Of the remaining 5,703 patients, 
3,603 (63.2%) were admitted and 2,100 (36.8%) were discharged 
from ED/EC. The median cs-cTnI for admitted patients was 9 ng/L 
(IQR 4–18) with a 99th percentile of 1,162 ng/L and 439 (12.2%) 
were above the ULN, while for those patients not admitted the 
median was 5 ng/L (IQR 2–9) with a 99th percentile of 67 ng/L and 
49 (2.3%) were above the ULN (p<0.001). The rate of admission 
increased with increasing cs-cTnI concentrations regardless of 
whether the test was clinically requested or not (Table 2).
Once patients in whom the hs-cTnI was clinically requested were 
excluded, the median cs-cTnI for admitted patients was 8 ng/L 
(IQR 4–17) with a 99th percentile of 600 ng/L and 264 (10.1%) 
were above the ULN, while for those patients not admitted the 
median was 5 ng/L (IQR 2–9) with a 99th percentile of 69 ng/L 
and 42 (2.7%) were above the ULN (p<0.001).
Cause of cs-cTnI elevation
A cardiovascular diagnosis (27.5%) was the most frequent 
discharge diagnosis in those with an cs-cTnI above the ULN 
(supplementary material, S1). However, a neurological or a 
respiratory condition (13.6%) was most common in the patients 
in whom the test was only requested as part of the study and 
therefore the result was not available to the clinical team as 
there was no suspicion of an acute coronary syndrome. Table 3 
highlights the mortality and distribution of hs-cTnI for each 
cardiovascular discharge diagnosis. Patients with a T1MI had 
higher cs-cTnI concentrations than the rest of the patients with cs-
cTnI above the ULN (227 ng/L (101–1,357) and 69 ng/L (52–151), 
respectively; p<0.001).
Hospital length of stay and 30-day mortality
One-hundred and fifty (2.6%) patients died within 30 days of their 
presentation to ED. None of the patients that had an undetectable 
cs-cTnI died but there was an associated increase in mortality and 
length of stay with increasing cs-cTnI concentration, in both the 
whole cohort (Fig 2) and in those only having cs-cTnI testing as 
part of the study whose result was not available to the supervising 
clinical team because there was no clinical suspicion of acute 
coronary syndrome (Fig 3). The discriminatory ability of cs-cTnI 
concentration for 30-day mortality for the whole cohort was 0.863 
Table 1. Frequency of cs-cTnI above the 99th 
percentile across emergency department locations
Location Percentage of patients 






Eye casualty n/a 0.0%
Minors 0.0% 2.0%
Clinical decision unit 0.0% 5.0%
Majors 5.7% 7.2%
Generic emergency department 8.0% 6.2%
Resuscitation 19.3% 28.8%











0 ng/L 52.0% 49.7% 52.7%
1–9 ng/L 55.3% 54.9% 55.5%
10–19 ng/L 70.5% 69.6% 70.9%
20–40 ng/L 79.8% 79.7% 79.8%
>40 ng/L 90.0% 96.2% 86.3%
Fig 1. Bar chart to demonstrate the frequency of cs-cTnI above upper 
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(95% CI 0.838–0.888) and it was 0.859 (95% CI 0.830–0.888) for 
those in whom the test was only performed as part of the study. 
Table 4 demonstrates the specificity, sensitivity, PPV and NPV derived 
from the ROC analysis for different cs-cTnI thresholds. The log(10) 
cs-cTnI was independently associated with 30-day mortality for the 
whole cohort (HR 2.326; 95% CI 1.872–2.892) – see supplementary 
material S2 for remainder of covariables. Furthermore, once all the 
patients in whom the cs-cTnI was requested on clinical grounds were 
Table 3. Frequency of cardiovascular discharge diagnoses, the spread of cs-cTnI and the associated 30-day 
mortality








Arrhythmia 150 13 6–25 27 (18.0) 1 (0.7)
Heart failure 45 38 22–84 20 (44.4) 5 (11.1)
Acute coronary syndrome 90 112 29–657 63 (70.0) 7 (7.8)
Cardiac arrest / cardiogenic shock 5 70 41–787 4 (80.0) 3 (60.0)
Valvular heart disease 10 26 7–33 1 (10.0) 2 (20.0)
Pericardial diseases 17 11 6–55 5 (29.4) 0
Stable ischaemic heart disease 39 16 10–39 8 (20.5) 0
Hypertension 10 10 7–30 1 (10.0) 0
Aortic diseases 3 14 n/a 0 1(33.3)
Myocarditis 4 51 15–869 3 (75.0) 0
Device infection 5 37 13–368 2 (40.0) 1 (20.0)
Other 39 4 0–8 1 (2.6) 0
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Fig 2. a) Median length of stay across cs-cTnI groups for the whole 
cohort. b) Thirty-day mortality across cs-cTnI groups for the whole 
cohort.
Fig 3. a) Median length of stay across cs-cTnI groups for those in whom 
the test was only performed as part of the study and the clinician was 
unaware of the result because there was no clinical suspicion of acute 
coronary syndrome. b) Thirty-day mortality across cs-cTnI groups for 
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excluded, cs-cTnI remained independently associated with 30-day 
mortality (HR 2.533; 95% CI 1.932–3.321) – see supplementary 
material S2 for remainder of covariables.
The relationship between the area of assessment within ED 
and with subsequent mortality and length of stay is shown in 
Table 5.
Patients discharged with a cs-cTnI above the 99th 
percentile
There were 85 patients with cs-cTnI concentrations above the ULN 
who were either discharged within 24 hours of admission or direct 
from ED (supplementary material S3). Specifically, seven patients 
were discharged direct from ED with cs-cTnI concentrations 
above the ULN that the clinicians had requested with the 
following discharge diagnoses: atrial fibrillation;2 supraventricular 
tachycardia; heart failure; abdominal pain; non-specific chest pain; 
and general anxiety.
Discussion
To our knowledge this is the largest study to assess cs-cTnI 
concentrations in a consecutive group of patients presenting to ED 
regardless of clinical status, and the first to report the association 
between cs-cTnI concentration and 30-day mortality in this 
population. Our study reports several key findings. First, cs-cTnI 
concentrations above the ULN are frequently seen in patients 
presenting to ED (7.6%) and this appears to be associated with 
the severity of their condition, as defined by the ED location, with 
nearly 1 in 5 patients above the ULN in the resuscitation area. 
Second, a wide range of cardiovascular and non-cardiovascular 
diagnoses are associated with cs-cTnI elevation. Third, and most 
important, cs-cTnI concentrations on arrival to ED are associated 
with short-term mortality and length of stay, regardless of whether 
there was a clinical indication to perform the assay.
While this study demonstrates that, in patients presenting to ED, 
concentrations of cs-cTnI are frequently (7.6%) above the ULN, 
previous studies have reported much higher frequencies, even 
with non-contemporary-sensitivity assays.14,18–21 This is because 
the majority of these studies, in contrast to our study, included 
only patients in whom the test was clinically requested. There 
are two studies that have performed high-sensitivity cTn testing 
regardless of the clinical indication in consecutive patients in ED. 
The first of these, which excluded patients who were under 65 
years of age and who were not admitted from ED, found a much 
higher prevalence (52% of 679 patients) of high-sensitivity cTnT 
above the ULN, which is likely to be explained by the greater 
age.16,18–20,22 Shah et al studied a cohort of 1,054 consecutive 
patients presenting to ED in whom a high-sensitivity cTnI test was 
added onto their routine blood sample and this result was withheld 
from the clinical team.14 The prevalence of high-sensitivity cTnI 
above the ULN was nearly twice as high (13.7%) in their cohort 
when compared to the current study. There are a number of 
potential reasons for this variation: first, it maybe that the severity 
of illness was different between these populations (however, the 
similar admission rates (63.2% vs 57.8%) suggest that this is not a 
major consideration); second, and probably more important, the 
assays used in these studies were different and so it is possible 
that the variation in prevalence results from differences in the 
assay performance. The high prevalence of cs-cTnI above the 
ULN in patients presenting to ED highlights the potential flaws in 
the application of the manufacturer-supplied 99th percentile as a 
universal ULN across all patients.8,16
The observation that patients in the resuscitation department 
had the highest cs-cTnI concentrations is likely to be explained 
by these patients being the most unwell in the department, since 
Table 4. Diagnostic performance parameters for cs-cTnI cut off thresholds for mortality
Cohort Cs-cTnI threshold 
relative to ULN




Whole population >ULN 48.0% 92.5% 13.7% 98.4%
>10 × ULN 13.3% 98.9% 24.7% 97.7%
Study requested cohort >ULN 44.4% 93.6% 16.7% 98.3%
>10 × ULN 9.4% 99.3% 27.5% 97.4%
Cs-cTnI = contemporary sensitivity troponin I; ULN = upper limit of normal.
Table 5. Cs-cTnI spread, length of stay and mortality by emergency department location and whether the 
test was clinically requested
Location Median cs-cTnI (IQR), ng/L P value Median length of stay 
(IQR), days













Resus 21 (9–49) 11 (5–29) <0.001 2 (0–7) 3 (1– 10) 0.112 17.9 10.9 0.039
Majors 7 (3–12) 6 (2–12) 0.203 0 (0–1) 0 (0–2) <0.001 1.4 1.2 0.649
Generic ED 7 (3–12) 8 (3–14) 0.001 0 (0–1) 1 (0–4) <0.001 0.1 3.4 <0.001
Cs-cTnI = contemporary sensitivity troponin I; ED = emergency department; IQR = interquartile range; Resus = resuscitation. Underlining highlights a statistically 
significantly higher result.
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increased illness severity has been demonstrated to be closely 
associated with cTn elevation, not only in ED, but also in the 
context of sepsis and patients admitted to intensive care.23–27
The most important observation of this study is that increasing 
cs-cTnI concentrations (regardless of the manufacturer’s 99th 
percentile value) are associated with increasing 30-day mortality. 
Furthermore, the AUCs of 0.863 and 0.859 suggest that cs-cTnI 
testing on admission, outside of the context of acute T1MI, could 
provide useful prognostic information for clinicians about the 
patients newly presented to them. This concept is consistent with 
previous data from outpatient populations with chronic diseases 
suggesting that the cs-cTn concentration is associated with future 
cardiovascular events, and that the assay may therefore represent 
a biomarker for cardiovascular risk.9,28,29 These observations 
warrant further study to assess whether cs-cTn could represent a 
prognostic biomarker for patients presenting to ED.
Strengths and limitations of this study
This study provides a unique insight into the distribution of 
cs-cTnI within the population of patients presenting to ED as a 
result of its large, consecutive and prospective collection of the 
samples. The key limitation for this study is that the clinical data 
were collected using the coding system or the online clinical 
record. Clinical coding is key to the financial credibility of NHS 
institutions and therefore attempts are made to ensure that it 
is as accurate as possible. A large recent study, however, raises 
concern about its accuracy by demonstrating that in 16.8% 
of cases reviewed later, the primary diagnosis was changed.30 
Given the concern about the robustness of comorbidity coding, 
particularly within the ED environment, we have not included 
comorbidity data in the multivariable analysis. The recording of 
the length of stay and mortality is less subjective and therefore 
allows robust conclusions to be drawn. A second important 
limitation of this study is that we only added cs-cTnI testing 
onto the first sample received for each patient in CHARIOT, but, 
given the evidence that more patients develop cTn elevation with 
time and the change in cTn may have further prognostic value, 
further studies are needed to assess whether these parameters 
provide better prognostic information.11 Finally, while the assay 
used in this study was in use as a high-sensitivity cTn assay at our 
institution, and others, it only approaches the threshold to be 
classified as a true high-sensitivity assay and could be considered 
a contemporary sensitivity assay. This may mean that the 
thresholds described in this study may not be directly transferable 
to a truly high-sensitivity assay, but this should not change the 
overall interpretation of the results.
Conclusions
In this consecutive population of patients presenting to the ED, 
in whom the assay was performed without the knowledge of 
the clinical supervising team unless it was specifically requested 
by them, cs-cTnI elevation is common and is associated with 
increasing age and illness severity. Furthermore, increasing cs-cTnI 
concentrations are associated with longer hospital admissions and 
short-term mortality and may therefore provide useful prognostic 
information to clinicians. Given these data, further studies are 
now required to assess whether cs-cTn could represent a biomarker 




 > Troponin testing forms a central part of the algorithm for 
the diagnosis of myocardial infarction in the emergency 
department (ED), as recommended by international 
guidelines.
 > A range of clinical factors are known to be associated with 
troponin concentrations above the manufacturer-defined 
upper limit of normal.
 > There is emerging evidence that higher-sensitivity troponin 
assays may have a role in prognosis even in patients without 
a presentation consistent with myocardial infarction.
What is the question?
 > The study aimed to test whether a contemporary sensitivity 
troponin (cs-cTn), measured in ED, may be a biomarker 
for clinical outcome, irrespective of the indication for its 
measurement.
What was found?
 > In a consecutive population of 5,708 patients presenting 
to ED, increasing contemporary sensitivity troponin 
concentrations were associated with increasing hospital 
admission, length of stay and mortality
 > Contemporary sensitivity troponin testing is already being 
performed outside its original purpose. These results should 
help further inform clinicians about the importance of 
interpreting abnormal contemporary sensitivity troponin 
results in the clinical context.
What is the implication for practice now?
 > These results should help further inform clinicians about the 
importance of interpreting contemporary sensitivity troponin 
results in the clinical context.
 > This study suggests that contemporary sensitivity troponin 
may provide a useful marker of prognosis on presentation to 
the emergency medical services.
 > Further study is now required to evaluate the role of high-
sensitivity troponin as a prognostic marker in other contexts 
and to assess whether any medical interventions can alter the 
prognosis in these patients.
Supplementary material
Additional supplementary material may be found in the online 
version of this article at www.rcpjournals.org/clinmedicine:
S1 – Discharge diagnosis categories in patients with a cs-cTnI 
above the upper limit of normal for all patients and then split by 
whether the supervising clinician requested the test.
S2 – Cox regression covariables for the whole cohort and for those 
in whom the cs-cTnI test was performed solely as part of the 
study, in whom the clinicians had no suspicion of acute coronary 
syndrome.
S3 – Discharge diagnoses of patients with a hs-cTnI above the 
upper limit of normal discharged from ED or within 24 hours of 
admission.
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